Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on July 29, 2022, before market opens. A live webcast of the earnings conference call will take place at 8 a.m. CT and will be accessible on AbbVie's Investor Relations website. An archived version will be available later that day. AbbVie aims to address serious health issues through innovative medicines across various therapeutic areas including immunology, oncology, and more.
AbbVie kicks off its seventh Week of Possibilities on June 27, 2022, engaging around 15,000 employees in global volunteer efforts spanning over 50 countries. This event, running from June 27 to July 1, aims to strengthen local communities through projects like renovating schools and playgrounds. Notable initiatives include creating STEM Labs and supporting Ukrainian refugees. The company's commitment to community service underscores its corporate citizenship, previously recognized as a top "Companies that Care" by Great Place to Work®.
AbbVie announced the positive opinion from the European Medicines Agency's CHMP for upadacitinib (RINVOQ) to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA). This decision is based on the successful results from the Phase 3 SELECT-AXIS 2 study, where RINVOQ met its primary endpoint of ASAS40 response at week 14 versus placebo. The European Commission's decision is anticipated in Q3 2022. Upadacitinib is currently approved for various conditions, but its use in nr-axSpA remains under review in both the EU and U.S.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on August 15, 2022, for stockholders of record by July 15, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250% and is part of the S&P Dividend Aristocrats Index, recognized for consistent annual dividend increases for over 25 years. This marks a continued commitment to returning value to shareholders while focusing on innovative therapeutic solutions.
AbbVie has submitted a supplemental New Drug Application (sNDA) for atogepant (QULIPTA) to the FDA, aiming to expand its indication for preventing chronic migraines in adults. This follows the pivotal Phase 3 PROGRESS trial, which demonstrated a statistically significant reduction in mean monthly migraine days compared to placebo. If approved, atogepant will be the first gepant available for chronic migraine treatment, positioning AbbVie as the only company with two preventive treatments for chronic migraines, alongside BOTOX.
Allergan Aesthetics, part of AbbVie, launched 'The Future of Aesthetics' global trends report to help the industry navigate evolving consumer needs. The report, developed with Wunderman Thompson Intelligence, involved extensive research and interviews with leading practitioners. It highlights a surge in dermal filler treatments, growing consumer diversity in aesthetics, and ten major trends expected to shape the industry over the next five years. Carrie Strom emphasized the importance of understanding these trends for future growth and innovation in aesthetics.
AbbVie announced FDA approval for SKYRIZI (risankizumab-rzaa) as the first specific interleukin-23 (IL-23) inhibitor for moderately to severely active Crohn's disease in adults. Supported by data from three clinical trials, SKYRIZI showed significant improvement in clinical response and remission at various intervals. The treatment involves an initial intravenous infusion followed by subcutaneous injections. This approval marks a significant advancement in options for Crohn's disease patients, which affects daily life due to unpredictable symptoms.
AbbVie reports positive results from the EPCORE NHL-1 phase 2 trial of epcoritamab for relapsed/refractory large B-cell lymphoma (LBCL). The study showed an overall response rate (ORR) of 63% with a complete response (CR) of 39%. Notably, CAR T-naïve patients had a 69% ORR and 42% CR. The safety profile was consistent with prior data, with most adverse effects occurring in the initial treatment phase. These findings were presented at the EHA's Presidential Symposium, highlighting a significant advancement in treatment options for LBCL.
AbbVie announced preliminary data from the Phase 2 REFINE study, showing positive early results for navitoclax combined with ruxolitinib in treating JAK inhibitor naïve myelofibrosis (MF) patients. Data revealed a 63% spleen volume reduction of ≥35% at week 24. Additionally, 41% of evaluable patients reported a ≥50% reduction in symptom scores. No new safety signals were identified, though 97% of patients reported adverse events, with thrombocytopenia being the most common. These findings could support further exploration of navitoclax as a treatment to modify disease progression.
